Business Wire02.08.17
Glaukos Corporation, an ophthalmic medical technology company developing and commercializing breakthrough products and procedures to treat glaucoma, named Chris M. Calcaterra as chief operating officer (COO), effective immediately.
Calcaterra joined Glaukos in 2008 and has served as its chief commercial officer since that time. With his promotion to COO, Calcaterra will continue to lead the company’s global sales, marketing and reimbursement functions, while adding oversight of manufacturing operations, facilities management and clinical recruiting to his management responsibilities.
Calcaterra has more than 25 years of experience in the ophthalmic medical technology industry. Prior to joining Glaukos, he was a senior vice president responsible for the cataract business at Advanced Medical Optics Inc. (AMO), which was acquired by Abbott Laboratories in 2009. He previously held increasingly responsible leadership positions in a variety of sales and marketing roles at AMO, as well as AMO’s predecessor surgical division business at Allergan Inc.
“Chris has been instrumental in the growth and development of Glaukos since joining our management team nearly nine years ago and I am confident that he will continue to play an integral role in our success in the newly created chief operating officer position,” said Thomas Burns, Glaukos president and CEO. “His sales and marketing prowess, leadership, sound judgement, competitive spirit and reputation across the ophthalmic professional community and industry make him an ideal individual for this expanded leadership responsibility.”
Calcaterra has a bachelor’s degree from Miami University and a master’s degree in business administration from Xavier University.
Glaukos pioneered micro-invasive glaucoma surgery (MIGS) to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent, its first MIGS device, in the United States in July 2012 and is leveraging its platform technology to build a proprietary portfolio of micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression. The San Clemente, Calif.-based company believes the iStent, measuring 1 mm long and 0.33 mm wide, is the smallest medical device ever approved by the U.S. Food and Drug Administration.
Watch the video below to learn more about the iStent:
Calcaterra joined Glaukos in 2008 and has served as its chief commercial officer since that time. With his promotion to COO, Calcaterra will continue to lead the company’s global sales, marketing and reimbursement functions, while adding oversight of manufacturing operations, facilities management and clinical recruiting to his management responsibilities.
Calcaterra has more than 25 years of experience in the ophthalmic medical technology industry. Prior to joining Glaukos, he was a senior vice president responsible for the cataract business at Advanced Medical Optics Inc. (AMO), which was acquired by Abbott Laboratories in 2009. He previously held increasingly responsible leadership positions in a variety of sales and marketing roles at AMO, as well as AMO’s predecessor surgical division business at Allergan Inc.
“Chris has been instrumental in the growth and development of Glaukos since joining our management team nearly nine years ago and I am confident that he will continue to play an integral role in our success in the newly created chief operating officer position,” said Thomas Burns, Glaukos president and CEO. “His sales and marketing prowess, leadership, sound judgement, competitive spirit and reputation across the ophthalmic professional community and industry make him an ideal individual for this expanded leadership responsibility.”
Calcaterra has a bachelor’s degree from Miami University and a master’s degree in business administration from Xavier University.
Glaukos pioneered micro-invasive glaucoma surgery (MIGS) to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent, its first MIGS device, in the United States in July 2012 and is leveraging its platform technology to build a proprietary portfolio of micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression. The San Clemente, Calif.-based company believes the iStent, measuring 1 mm long and 0.33 mm wide, is the smallest medical device ever approved by the U.S. Food and Drug Administration.
Watch the video below to learn more about the iStent:
